EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

When Rosuvastatin Meets Curcumin: Preclinical Insight into Novel Synergistic Combination

Belma Pehlivanović Kelle, Dina Lagumdžija, Tarik Suljić, Aida Hamzić-Mehmedbašić, Jasna Kusturica, Aida Kulo Ćesić

Future Pharmacology · 18.08.2026 · 6 (3) · 45

DOI: 10.3390/futurepharmacol6030045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 18.08.2026. Verfasst von Belma Pehlivanović Kelle und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rosuvastatin, a potent lipid-lowering statin, and curcumin, a bioactive naturally occurring polyphenolic phytochemical, both show pleiotropic antioxidant and anti-inflammatory properties. In addition, curcumin shows also antimicrobial, anticancer, hypolipidemic and antifibrotic effects. From the pharmacodynamic point, rosuvastatin and curcumin target overlapping molecular pathways—suggesting possible pharmacodynamic synergy that has emerged as a promising therapeutic approach in the management of various diseases, including cardiovascular, metabolic, kidney, and inflammatory diseases.

Objectives

This review aimed to systematically summarize and critically evaluate all available preclinical data concerning the combined use of rosuvastatin and curcumin, emphasizing their possible synergistic effects.

Methods

A total of seven preclinical studies that investigated the combination of curcumin and rosuvastatin, three in vitro and four in vivo, conducted between 2017 and 2025, were included in the analysis.

Results

While in vitro studies suggested a promising synergy in lipid-lowering, antioxidant, and anti-inflammatory effects, in vivo findings confirmed enhanced lipid-lowering effects, potential hepatoprotection and nephroprotection when two agents are co-administered. In addition to pharmacodynamic interaction, pharmacokinetic studies also revealed that curcumin may increase systemic rosuvastatin exposure by inhibiting hepatic transporters, warranting further investigation into dosing and safety of the combination.

Conclusions

While current evidence supports the therapeutic potential of the combined use of rosuvastatin and curcumin, additional pharmacokinetic, mechanistic, and clinical studies are needed to fully assess its translational value.

Zitieren

APA

Kelle, B. P., Lagumdžija, D., Suljić, T., Hamzić-Mehmedbašić, A., Kusturica, J., & Ćesić, A. K. (2026). When Rosuvastatin Meets Curcumin: Preclinical Insight into Novel Synergistic Combination. Future Pharmacology, 6(3), 45. https://doi.org/10.3390/futurepharmacol6030045

Vancouver

Kelle BP, Lagumdžija D, Suljić T, Hamzić-Mehmedbašić A, Kusturica J, Ćesić AK. When Rosuvastatin Meets Curcumin: Preclinical Insight into Novel Synergistic Combination. Future Pharmacology. 2026;6(3):45. doi:10.3390/futurepharmacol6030045

BibTeX
@article{Kelle2026,
  author = {Kelle, Belma Pehlivanović and Lagumdžija, Dina and Suljić, Tarik and Hamzić-Mehmedbašić, Aida and Kusturica, Jasna and Ćesić, Aida Kulo},
  title = {When Rosuvastatin Meets Curcumin: Preclinical Insight into Novel Synergistic Combination},
  journal = {Future Pharmacology},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {45},
  doi = {10.3390/futurepharmacol6030045}
}
Kostenlos starten →